Dov Shamir

Founding Head, Elementa Labs
Mount Sinai Health System​

Dov Shamir, PhD is a neuroscientist, investor, and innovator based in New York City. He serves as the Founding Head of Elementa Labs and Assistant Director of Entrepreneurship at Mount Sinai Innovation Partners (MSIP), the commercialization office of the Mount Sinai Health System. He created Elementa Labs to support and scale early-stage healthcare and biotechnology startups to foster innovation in the healthcare sector, improve patient outcomes and operational efficiency in healthcare. Notable companies in his Elementa portfolio include AVO, Curio Digital Therapeutics, Empo Health, JelikaLite, Nest Genomics, OBELAB, and Vivo Surgical.
Dov has applied his multidisciplinary background in therapeutic development, engineering, business development, and finance to create his own startups and technologies. He earned his PhD in Neuroscience and Physiology from NYU’s Grossman School of Medicine. His research included developing immunotherapies for Alzheimer’s disease and creating innovative in vitro bioreactor platform devices. He also holds a Bachelor of Arts in Economics from Yeshiva University and certificates in Finance from NYU’s Stern School of Business.​

 

Speech title & Synopsis

US Healthcare Market and Innovation

Although today’s international trade environment is complex, the United States (US) of America maintains an attractive market of interest for companies to expand their healthcare business. With an aging population and chronic diseases on the rise the need for innovation has only become more critical. The use of artificial intelligence, machine learning, and other digital approaches has provided a unique opportunity in creating new solutions and efficiencies, scale existing technology modalities, providing better healthcare access and reduce costs. The US market has provided a unique mix of research & development, financing, human capital, and policy to make this a reality. To continue this growth, the US market needs to further access the world’s most innovative ideas, people, markets, and companies.  This will require US entities (like hospitals and industry) to identify synergistic solutions and partners, while international entities will need to signal the value of their solutions within the US healthcare workflow and marketplace.